Edwards Lifesciences 관리

관리 기준 확인 2/4

Edwards Lifesciences CEO는 Bernard Zovighian, May2023 에 임명되었습니다 의 임기는 1.58 년입니다. 총 연간 보상은 $ 12.87M, 7.6% 로 구성됩니다. 7.6% 급여 및 92.4% 보너스(회사 주식 및 옵션 포함). 는 CHF 4.78M 가치에 해당하는 회사 주식의 0.012% 직접 소유합니다. 4.78M. 경영진과 이사회의 평균 재임 기간은 각각 5.3 년과 4.6 년입니다.

주요 정보

Bernard Zovighian

최고 경영자

US$12.9m

총 보상

CEO 급여 비율	7.6%
CEO 임기	1.6yrs
CEO 소유권	0.01%
경영진 평균 재임 기간	5.3yrs
이사회 평균 재임 기간	4.6yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Bernard Zovighian 의 보수는 Edwards Lifesciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	US$2b
Jun 30 2024	n/a	n/a	US$2b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$13m	US$973k	US$1b
Sep 30 2023	n/a	n/a	US$1b
Jun 30 2023	n/a	n/a	US$1b
Mar 31 2023	n/a	n/a	US$1b
Dec 31 2022	US$3m	US$642k	US$2b

보상 대 시장: Bernard 의 총 보상 ($USD 12.87M )은 Swiss 시장( $USD 4.69M ).

보상과 수익: Bernard 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Bernard Zovighian (56 yo)

1.6yrs

테뉴어

US$12,869,020

보상

Mr. Bernard J. Zovighian serves as Chief Executive Officer and Director at Edwards Lifesciences Corp since May 11, 2023 and was its President at Edwards Lifesciences Corp since January 1, 2023 until May 11...

리더십 팀

이름	위치	테뉴어	보상	소유권
Bernard Zovighian	CEO & Director	1.6yrs	US$12.87m	0.012% CHF 4.8m
Scott Ullem	Corporate VP & CFO	10.9yrs	US$5.95m	0.046% CHF 18.3m
Donald Bobo	Corporate Vice President of Strategy & Corporate Development	8.8yrs	US$4.29m	0.035% CHF 13.8m
Larry Wood	Corporate VP and Group President of TAVR & Surgical Structural Heart	1.9yrs	US$5.40m	0.030% CHF 11.9m
Andrew Dahl	Principal Accounting Officer	less than a year	데이터 없음	0.00030% CHF 118.2k
Todd Brinton	Corporate VP of Advanced Technology & Chief Scientific Officer	5.8yrs	데이터 없음	데이터 없음
Mark Wilterding	Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Arnold Pinkston	Corporate VP & General Counsel	5.3yrs	데이터 없음	데이터 없음
Dirksen Lehman	Corporate Vice President of Public Affairs	11.5yrs	데이터 없음	데이터 없음
Christine McCauley	Corporate Vice President of Human Resources	12.3yrs	데이터 없음	데이터 없음
Gary Sorsher	Senior Vice President of Quality & Regulatory Compliance	1.4yrs	데이터 없음	데이터 없음
Wayne Markowitz	GM & Senior VP of Surgical Structural Heart	1.3yrs	데이터 없음	0.00012% CHF 47.3k

5.3yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: 001065343 의 관리팀은 노련하고 경험 (평균 재직 기간 5.3 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Bernard Zovighian	CEO & Director	1.6yrs	US$12.87m	0.012% CHF 4.8m
Kieran Gallahue	Independent Director	9.8yrs	US$335.06k	0.012% CHF 4.8m
Paul LaViolette	Independent Director	4.4yrs	US$329.97k	0.0013% CHF 516.2k
Steven Loranger	Independent Director	8.8yrs	US$335.06k	0.012% CHF 4.8m
Leslie Heisz	Independent Director	8.4yrs	US$356.42k	0.0046% CHF 1.8m
Nicholas Valeriani	Independent Chairman	10.1yrs	US$347.97k	0.012% CHF 4.6m
Leslie Davis	Independent Director	less than a year	데이터 없음	데이터 없음
David Feinberg	Director	less than a year	데이터 없음	데이터 없음
Ramona Sequeira	Independent Director	4.6yrs	US$334.97k	0.0019% CHF 736.8k

4.6yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: 001065343 의 이사회는 경험(평균 재직 기간 4.6 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/23 05:55
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Edwards Lifesciences Corporation 74 애널리스트 중 33 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
James Francis Mainwaring	Atlantic Equities LLP
David Rescott	Baird
Ishan Majumdar	Baptista Research

Edwards Lifesciences 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Insufficient new directors

Edwards Lifesciences Corporation, Annual General Meeting, May 07, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Edwards Lifesciences Corporation, Annual General Meeting, May 11, 2023

Recent updates

Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data

Third quarter 2024 earnings released: EPS: US$0.61 (vs US$0.55 in 3Q 2023)

Edwards Lifesciences Corporation Presents Data at TCT Reinforce Commitment to Structural Heart Innovation

TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation

Edwards Lifesciences Announces Results from the EARLY TAVR Trial

Edwards Lifesciences Corporation Provides Earnings Guidance for the Fourth Quarter and Reiterates Sales Guidance for the Full Year 2024

Edwards Lifesciences Corporation to Report Q3, 2024 Results on Oct 24, 2024

Robbins Geller Rudman & Dowd LLP Updates on Class Action Lawsuit Against Edwards Lifesciences Corporation

Edwards Launches SAPIEN 3 With Alterra Prestent in Europe for Transcatheter Pulmonic Valve Implantation

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW).

Edwards Lifesciences Corporation Provides Earnings Guidance for the Third Quarter of 2024

Edwards Lifesciences Corporation (NYSE:EW) agreed to acquire the remaining unknown majority stake in Innovalve Bio Medical Ltd. for $300 million.

Edwards Lifesciences Announces Results from Analysis of Data from Partner Trials Examining Outcomes of Transcatheter Aortic Valve Replacement Patients with Small Annulus

Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.

Edwards Lifesciences Corporation Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability

Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024

Edwards Lifesciences Corporation to Report Q1, 2024 Results on Apr 25, 2024

Edwards Lifesciences Announces the Release of Data from the Hudle Study

Insufficient new directors

Edwards Lifesciences Corporation, Annual General Meeting, May 07, 2024

Edwards Lifesciences Announces Large, Real-World Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR

Investor sentiment improves as stock rises 25%

Insufficient new directors

Edwards Lifesciences Corporation Provides Earnings Guidance for the First Quarter and Full Year 2024

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

Edwards Lifesciences Corporation to Report Q4, 2023 Results on Feb 06, 2024

Insufficient new directors

Edwards Lifesciences Corporation Reaffirms Earnings Guidance for the Year 2023 and Provides Earnings Guidance for the Full Year 2024

Edwards Lifesciences Corporation (NYSE:EW) announces an Equity Buyback for $1,000 million worth of its shares.

Clasp IID One-Year Data Confirm Safety and Efficacy of Edwards Pascal System for Degenerative Mitral Regurgitation

Edwards Lifesciences Corporation Provides Earnings Guidance for Full Year 2023 and Fourth Quarter of 2023

Edwards Lifesciences Corporation's Evoque Tricuspid Valve Replacement System Receives CE Mark

Edwards Lifesciences Corporation to Report Q3, 2023 Results on Oct 25, 2023

Edwards Lifesciences Corporation Announces the Results of the Eu-Hyprotect Registry

Insufficient new directors

Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023

Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023

Edwards Lifesciences Announces Results of the EU-HYPROTECT Registry

Edwards' Aortic Valve with Resilia Tissue Shows Favorable Durability, Safety and Efficacy Outcomes in Seven Year Data

First quarter 2023 earnings released: EPS: US$0.56 (vs US$0.60 in 1Q 2022)

Edwards Lifesciences Corporation to Report Q4, 2022 Results on Jan 31, 2023

Edwards Lifesciences Corporation Provides Earnings Guidance for the Full Year 2023

Edwards Lifesciences Corporation, Annual General Meeting, May 11, 2023

Edwards Lifesciences Corporation Announces One-Year Data on Transfemoral Transcatheter Tricuspid Valve Replacement

Edwards Lifesciences Corporation to Report Q3, 2022 Results on Oct 27, 2022

Edwards Lifesciences Corporation Announces Results from CLASP IID

Edwards Lifesciences Corporation's Transcatheter Edge-To-Edge Repair Receives FDA Approval

Edwards Lifesciences Corporation Launches SAPIEN 3 Ultra Resilia Valve Following FDA Approval

Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year of 2022

Edwards Lifesciences Corporation to Report Q2, 2022 Results on Jul 28, 2022

Investor sentiment deteriorated over the past week

Edwards Lifesciences Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2022

Edwards Lifesciences Corporation to Report Q1, 2022 Results on Apr 26, 2022

Edwards Lifesciences Corporation's MITRIS RESILIA Valve Receives FDA Approval for Mitral Replacement Surgeries

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Edwards Lifesciences Provides Earnings Guidance for the First Quarter and Full Year of 2022

Edwards Lifesciences Corporation Receives FDA Approval for SAPIEN 3 with Alterra Prestent for Transcatheter Pulmonic Valve Replacement

Edwards Lifesciences Corporation Provides Sales Guidance for Fiscal 2022

Independent Director recently bought CHF158k worth of stock

Third quarter 2021 earnings released: EPS US$0.55 (vs US$0.52 in 3Q 2020)

Second quarter 2021 earnings released: EPS US$0.79 (vs US$0.20 loss in 2Q 2020)

Edwards Lifesciences Announces Clinical and Economic Results from 3M Transcatheter Aortic Valve Replacement Economic Study and the Partner 3 Bicuspid Registry for SAPIEN 3 TAVR Study

Edwards Lifesciences Receives U.S. Food and Drug Administration Clearance for Hypotension Prediction Index Software for Noninvasive Acumen IQ Cuff

Edwards Lifesciences Corporation Presents Clinical Results from Transcatheter Mitral and Tricuspid Programs as Part of the Late-Breaking Clinical Trials at EuroPCR 2021

Independent Director has left the company

Edwards Lifesciences Corporation (NYSE:EW) announces an Equity Buyback for $1,000 million worth of its shares.

VP & Corporate Controller recently sold CHF1.1m worth of stock

First quarter 2021 earnings released: EPS US$0.54 (vs US$0.50 in 1Q 2020)